Evidence map›Paper›PMID 41511682›Full record

ArticleClinical & experimental metastasis2026

Breast cancer liver metastases and the impact of receptor expression on survival.

Ellen Hansson, Marcus Sundén, Charlotta Wadsten, Gunilla Rask, Anne Andersson, Malin Sund, Oskar Hemmingsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ellen Hansson *Department of Diagnostics and Intervention, Surgery, Umeå University, 901 85, Umeå, Sweden. ellen.hansson@umu.se.ORCID http://orcid.org/0009-0004-8402-6562
Marcus SundénDepartment of Diagnostics and Intervention, Surgery, Umeå University, 901 85, Umeå, Sweden.
Charlotta WadstenDepartment of Diagnostics and Intervention, Surgery, Umeå University, 901 85, Umeå, Sweden.
Gunilla RaskDepartment of Diagnostics and Intervention, Surgery, Umeå University, 901 85, Umeå, Sweden.
Anne AnderssonDepartment of Diagnostics and Intervention, Oncology Umeå University, 901 85, Umeå, Sweden.
Malin Sund *Department of Diagnostics and Intervention, Surgery, Umeå University, 901 85, Umeå, Sweden.ORCID http://orcid.org/0000-0002-7516-9543
Oskar Hemmingsson *Department of Diagnostics and Intervention, Surgery, Umeå University, 901 85, Umeå, Sweden.ORCID http://orcid.org/0000-0003-1732-168X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim was to determine the frequency of altered receptor expression between primary breast cancer and liver metastases, and to examine the impact of receptor expression on survival. The conversion frequency of estrogen- (ER), progesterone- (PgR) and human epidermal growth factor receptor 2 (HER2) was investigated. The prognostic value of the receptor status in the primary tumor versus the metastases was estimated. Data on a population-based regional cohort of 7292 breast cancer patients from 2009 to 2018 were collected from the National Breast Cancer Register. Biomarker expression and intrinsic subtype was studied among those who developed liver metastases with available histopathological records. The study included 311 patients with liver metastases. Conversion of ER, PgR and HER2 occurred in 16%, 47% and 12% of patients, respectively. The subtype converted in 26%. HER2 amplification in the primary tumor or metastases was associated with improved survival. Positive ER and PgR in breast cancer and positive ER in liver metastases were beneficial for survival. A combined primary tumor and metastasis receptor evaluation had the highest prognostic value. Receptor conversion from primary tumor to liver metastases is common. HER2 amplification and positive ER or PgR are associated with improved survival. Accordingly, luminal HER2 positive tumors have improved survival compared to other intrinsic subtypes. To personalize treatment for each patient, a liver biopsy is warranted at diagnosis of breast cancer liver metastases.

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesLiver NeoplasmsReceptors, EstrogenReceptors, ProgesteroneAdultAgedFemaleHumansMiddle AgedPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerBreast cancer liver metastasesEstrogen (ER)Human epidermal growth factor receptor 2 (HER2)Progesterone (PgR)Receptor conversion

Identifiers

PMID41511682
PMCPMC12789201

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.